Cleared Traditional

K163633 - cobas HbA1c Test, cobas b 101 system

K163633 is an FDA 510(k) clearance for cobas HbA1c Test, manufactured by Roche Diagnostics Operations. The device is a Class 2 Chemistry device with product code LCP cleared through the Traditional 510(k) pathway after a 218-day FDA review.

K163633 · Roche Diagnostics Operations · Chemistry device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Jul 2017
Decision
218d
Days
Class 2
Risk

K163633 is an FDA 510(k) clearance for the cobas HbA1c Test, cobas b 101 system. Classified as Assay, Glycosylated Hemoglobin (product code LCP), Class II - Special Controls.

Submitted by Roche Diagnostics Operations (Indianapolis, US). The FDA issued a Cleared decision on July 28, 2017 after a review of 218 days - an extended review cycle.

This device falls under the Chemistry FDA review panel, regulated under 21 CFR 864.7470 - the FDA in vitro diagnostics and chemistry framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the Chemistry review framework, consistent with the majority of Class II 510(k) submissions.

View all Roche Diagnostics Operations devices

FDA 510(k) Submission Details - K163633

510(k) Number K163633 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received December 22, 2016
Decision Date July 28, 2017
Days to Decision 218 days
Submission Type Traditional
Review Panel Chemistry (CH)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
130d slower than avg
Panel avg: 88d · This submission: 218d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

LCP Device Classification - Class 2, Special Controls

Product Code LCP Assay, Glycosylated Hemoglobin
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 864.7470
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Chemistry devices follow this clearance model.

Regulatory Peers - LCP Assay, Glycosylated Hemoglobin

All 208
Devices cleared under the same product code (LCP) and FDA review panel - the closest regulatory comparables to K163633.
ACE Hemoglobin A1c (HbA1c) Reagent
K170623 · Alfa Wassermann Diagnostic Technologies, LLC · Feb 2018
Alere Afinion HbA1c and ACR on Afinion 2 analyzer
K171650 · Abbott Rapid Diagnostics · Nov 2017
Lucica Glycated Albumin-L
K170147 · Asahi Kasei Pharma Corporation · Oct 2017
A1C EZ Glycohemoglobin Analysis System
K161533 · Biohermes Co., Ltd. · Jun 2017
CAPI 3 Hb A1c, MULTI-SYSTEM Hb A1C CAPILLARY CONTROLS (2)
K162281 · Sebia · Feb 2017
Diazyme Direct HbA1c Assay (Enzymatic, On-Board Lysis), Diazyme Direct HbA1c Assay Calibrator Set, Diazyme Direct HbA1c Assay Control Set
K160762 · Diazyme Laboratories · Nov 2016